A potent and selective degrader of the transcription factor STAT3 offers a new approach to a previously “undruggable” target.
Ian Demsky is a senior writer and public relations representative for the University of Michigan Rogel Cancer Center. Ian joined the cancer center communications team in 2019. Prior to that he served as director of communications for the U-M Life Sciences Institute and science editor for Medicine at Michigan Magazine.
Looking beyond DNA mutations to a combination of molecular features could help determine the best drug combinations for each patient.
As the opioid crisis unfolded, prescriptions for the narcotic alternative saw a two-fold increase despite unclear evidence of benefit for pain.
A subset of patients known as maximizers consume a high level of medical resources without clear evidence of better outcomes, a study found.
Speaking directly with a pathologist could help patients better understand their diagnosis and feel empowered, a survey of patient sentiment finds.
Christina Chapman, M.D., sits down for a discussion on diversity, equity and inclusion in medicine.